Drug safety system needs overhaul, experts say.
Joel B
JB
Finkelstein
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016265:Conflict of Interest; D017277:Drug Approval / Q000458:organization & administration; D064420:Drug-Related Side Effects and Adverse Reactions; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006801:Humans; D018156:Journalism, Medical; D010080:Oxazoles / Q000009:adverse effects* / Q000494:pharmacology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D017594:Publication Bias; D014481:United States; D014486:United States Food and Drug Administration
D010080:Oxazoles; D047492:Peroxisome Proliferator-Activated Receptors; D005998:Glycine; C500085:muraglitazar